Trials / Terminated
TerminatedNCT05297045
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Regor Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGT001-075 | Oral GLP1 Receptor Agonist |
| OTHER | Placebo | Placebo comparator |
Timeline
- Start date
- 2022-03-29
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
- First posted
- 2022-03-25
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05297045. Inclusion in this directory is not an endorsement.